XW0Q316
Introduction Cranial Cavity and Brain to New Technology Group 6 with Eladocagene exuparvovec, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | Q Cranial Cavity and Brain |
| Approach | 3 Percutaneous |
| Device | 1 Eladocagene exuparvovec |
| Qualifier | 6 New Technology Group 6 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Cranial Cavity and Brain
The cranial cavity and brain as a combined body part reflects that some introduction procedures deliver a substance into the intracranial space generally rather than into a single named vessel or brain region, such as instillation of a novel agent into the subarachnoid or intraventricular space to treat conditions like recurrent hemorrhage or infection. Because the skull is a fixed, unyielding container, introducing anything into this compartment carries distinct risks around intracranial pressure and requires careful access planning, often through a burr hole or existing catheter. Documentation should clarify whether the substance reaches the ventricles, subdural space, or brain parenchyma broadly, since the New Technology designation signals an agent still under evaluation. Coders should verify operative notes describe the cranial cavity and brain as a unit rather than a more specific approvable structure.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Eladocagene exuparvovec
Eladocagene exuparvovec denotes administration of an AAV-based gene therapy delivered directly into the brain to treat aromatic L-amino acid decarboxylase (AADC) deficiency, a rare inherited neurotransmitter disorder. It works by introducing a functional copy of the AADC gene into neurons, distinguishing it from the hematopoietic stem cell gene therapies elsewhere in this list, which target blood-forming cells rather than the central nervous system.
Qualifier: New Technology Group 6
This value marks Group 6, the cohort of new technologies added for the 2019-2020 fiscal year. As with every group qualifier in this section, it is a bookkeeping label showing when a technology earned a distinct code rather than a clue to its function, which is conveyed through the accompanying device or substance value. It should not be read as interchangeable with Group 5 or Group 7.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.